title: Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
abstract: BACKGROUND
  Mifepristone (MF) has been largely used in reproductive medicine due to its capacity to modulate the progesterone receptor (PR). The study of MF has been expanded to the field of oncology; yet it remains unclear whether the expression of PR is required for MF to act as an anti-cancer agent. Our laboratory has shown that MF is a potent inhibitor of ovarian cancer cell growth. In this study we questioned whether the growth inhibitory properties of MF observed in ovarian cancer cells would translate to other cancers of reproductive and non-reproductive origin and, importantly, whether its efficacy is related to the expression of cognate PR.
  
  
  METHODS
  Dose-response experiments were conducted with cancer cell lines of the nervous system, breast, prostate, ovary, and bone. Cultures were exposed to vehicle or increasing concentrations of MF for 72 h and analysed for cell number and cell cycle traverse, and hypodiploid DNA content characteristic of apoptotic cell death. For all cell lines, expression of steroid hormone receptors upon treatment with vehicle or cytostatic doses of MF for 24 h was studied by Western blot, whereas the activity of the G1/S regulatory protein Cdk2 in both treatment groups was monitored in vitro by the capacity of Cdk2 to phosphorylate histone H1.
  
  
  RESULTS
  MF growth inhibited all cancer cell lines regardless of tissue of origin and hormone responsiveness, and reduced the activity of Cdk2. Cancer cells in which MF induced G1 growth arrest were less susceptible to lethality in the presence of high concentrations of MF, when compared to cancer cells that did not accumulate in G1. While all cancer cell lines were growth inhibited by MF, only the breast cancer MCF-7 cells expressed cognate PR.
  
  
  CONCLUSIONS
  Antiprogestin MF inhibits the growth of different cancer cell lines with a cytostatic effect at lower concentrations in association with a decline in the activity of the cell cycle regulatory protein Cdk2, and apoptotic lethality at higher doses in association with increased hypodiploid DNA content. Contrary to common opinion, growth inhibition of cancer cells by antiprogestin MF is not dependent upon expression of classical, nuclear PR.
authors: Division of Basic Biomedical Sciences, Sanford School of Medicine of The University of South Dakota, Vermillion, SD, USA.
authors: Chelsea R
authors: CR
authors: Tieszen
authors: Alicia A
authors: AA
authors: Goyeneche
authors: BreeAnn N
authors: BN
authors: Brandhagen
authors: Casey T
authors: CT
authors: Ortbahn
authors: Carlos M
authors: CM
authors: Telleria
references: Steroids. 2008 Oct;73(11):1160-73
references: 18603275
references: Anticancer Res. 2009 Apr;29(4):1053-8
references: 19414345
references: Neurosurgery. 1990 Sep;27(3):389-95; discussion 396
references: 2234331
references: Steroids. 2007 Jun;72(6-7):600-8
references: 17509631
references: J Clin Endocrinol Metab. 1993 Nov;77(5):1388-92
references: 8077338
references: J Biol Chem. 1999 Sep 24;274(39):27857-66
references: 10488132
references: Climacteric. 2003 Dec;6(4):285-92
references: 15006250
references: Fertil Steril. 1997 Dec;68(6):967-76
references: 9418681
references: Am J Reprod Immunol. 1995 Oct;34(4):248-56
references: 8579763
references: Mol Cell Biol. 1999 Jul;19(7):5036-49
references: 10373553
references: Br J Cancer. 2001 Dec 14;85(12):1978-86
references: 11747343
references: J Clin Endocrinol Metab. 1984 Sep;59(3):561-3
references: 6746867
references: Steroids. 2011 Jan;76(1-2):11-7
references: 20869977
references: J Clin Endocrinol Metab. 2008 May;93(5):1592-9
references: 18319313
references: J Clin Invest. 1994 Nov;94(5):1990-5
references: 7962545
references: Int J Oncol. 2009 Mar;34(3):743-55
references: 19212679
references: J Biol Chem. 2003 Aug 15;278(33):31136-48
references: 12771131
references: Jpn J Cancer Res. 2002 Jul;93(7):807-15
references: 12149147
references: J Steroid Biochem Mol Biol. 2002 Mar;80(3):307-13
references: 11948015
references: Cancer Cell Int. 2009 Feb 17;9:4
references: 19222856
references: Anticancer Res. 2009 Apr;29(4):1047-52
references: 19414344
references: Clin Cancer Res. 2007 Jun 1;13(11):3370-9
references: 17545545
references: J Soc Gynecol Investig. 1998 Nov-Dec;5(6):334-8
references: 9824816
references: Prostate. 1995 Apr;26(4):194-204
references: 7716084
references: Gynecol Oncol. 2001 Jul;82(1):127-38
references: 11426974
references: Expert Opin Pharmacother. 2008 Oct;9(14):2459-72
references: 18778184
references: J Biol Chem. 1973 Sep 10;248(17):6251-3
references: 4353636
references: Breast Cancer Res Treat. 1998 Sep;51(2):149-68
references: 9879777
references: Int J Oncol. 2003 Aug;23(2):369-80
references: 12851686
references: Mol Cell Biol. 2007 Mar;27(6):2266-82
references: 17242213
references: Cancer Res. 1983 Apr;43(4):1809-18
references: 6831420
references: Expert Opin Pharmacother. 2008 Oct;9(14):2473-85
references: 18778185
references: Endocrine. 2010 Oct;38(2):167-73
references: 21046477
references: Trends Endocrinol Metab. 1991 Nov-Dec;2(6):233-9
references: 18411188
references: Endocrinology. 1981 May;108(5):1703-9
references: 7194178
references: J Steroid Biochem Mol Biol. 2001 Aug;78(2):185-91
references: 11566443
references: Fertil Steril. 2000 Nov;74(5):1014-9
references: 11056251
references: Cancer Lett. 2000 Jun 30;154(2):151-61
references: 10806303
references: Cell Prolif. 2003 Jun;36(3):131-49
references: 12814430
references: Horm Cancer. 2010 Aug;1(4):167-76
references: 21761364
references: Prostate. 2001 Sep 15;48(4):285-91
references: 11536308
references: Endocrinology. 2002 Dec;143(12):4583-91
references: 12446585
references: Cancer Invest. 2006 Dec;24(8):727-33
references: 17162554
references: Endocrinology. 1985 Jun;116(6):2236-45
references: 4039656
references: Oncogene. 1996 Mar 7;12(5):999-1003
references: 8649817
references: Expert Opin Investig Drugs. 2008 Apr;17(4):469-79
references: 18363513
references: Pharmacol Ther. 2009 Jan;121(1):14-9
references: 18992768
references: Invest New Drugs. 2012 Jun;30(3):967-80
references: 21424700
references: Endocrinology. 2010 Jul;151(7):3204-13
references: 20484466
references: Expert Opin Pharmacother. 2008 Oct;9(14):2487-96
references: 18778186
references: Prostate. 2000 Feb 1;42(2):99-106
references: 10617866
references: Biochem Biophys Res Commun. 2009 Apr 17;381(4):671-5
references: 19248771
references: Endocrinology. 2007 Feb;148(2):705-18
references: 17082257
references: Breast Cancer Res Treat. 1998 Sep;51(1):39-55
references: 9877028
references: J Natl Cancer Inst. 2002 Mar 6;94(5):384-90
references: 11880477
references: Fertil Steril. 2005 Dec;84(6):1719-26
references: 16359971
references: Prostate. 2000 Apr 1;43(1):31-42
references: 10725863
references: Mol Cell Biol. 2003 Jun;23(12):4319-30
references: 12773573
references: Oncol Rep. 2006 Apr;15(4):743-8
references: 16525653
references: Hum Reprod Update. 2009 Jan-Feb;15(1):119-38
references: 18936037
references: Endocrinology. 2009 Nov;150(11):4846-54
references: 19797399
references: Clin Cancer Res. 2004 Aug 1;10(15):5215-25
references: 15297425
references: Carcinogenesis. 1999 Sep;20(9):1869-72
references: 10469636
references: J Clin Endocrinol Metab. 1992 Sep;75(3):865-70
references: 1517379
references: Anticancer Res. 2010 Dec;30(12):4835-40
references: 21187460